Gossamer Bio is trading 9.7% down at $0.18 as investors appeared to reassess dilution and financing overhang from its recently announced structured private placement.
- The deal includes pre-funded warrants priced at $0.1399 and potential additional securities tied to FDA milestones.
- XBI is up 2.06%, while recent consecutive advances leave room for profit-taking; sector momentum is not supporting the shares.
- No new company announcement dated August 26, 2026, was identified.